BioArctic receives milestone

BioArctic receives 1st milestone payment from Eisai. In December 2007, BioArctic Neuroscience AB signed an exclusive license agreement with Eisai Co., Ltd, where first milestone payment is connected to the submission of the IND to FDA.

The first clinical study with BAN2401 will include Alzheimer patients. BAN2401 is a humanized monoclonal antibody expected to halt the progression of Alzheimer´s disease.